|
1
|
Bray F, Laversanne M, Weiderpass E and
Soerjomataram I: The ever-increasing importance of cancer as a
leading cause of premature death worldwide. Cancer. 127:3029–3030.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waks AG and Winer EP: Breast cancer
treatment. JAMA. 321:3162019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bianchini G, De Angelis C, Licata L and
Gianni L: Treatment landscape of triple-negative breast
cancer-expanded options, evolving needs. Nat Rev Clin Oncol.
19:91–113. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Derakhshan F and Reis-Filho JS:
Pathogenesis of triple-negative breast cancer. Annu Rev Pathol.
17:181–204. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu M, Pan H, Che N, Li L, Wang C, Wang Y,
Ma G, Qian M, Liu J, Zheng M, et al: Microwave ablation of primary
breast cancer inhibits metastatic progression in model mice via
activation of natural killer cells. Cell Mol Immunol. 18:2153–2164.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kerr AJ, Dodwell D, McGale P, Holt F,
Duane F, Mannu G, Darby SC and Taylor CW: Adjuvant and neoadjuvant
breast cancer treatments: A systematic review of their effects on
mortality. Cancer Treat Rev. 105:1023752022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loibl S, Poortmans P, Morrow M, Denkert C
and Curigliano G: Breast cancer. Lancet. 397:1750–1769. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winkler F, Venkatesh HS, Amit M, Batchelor
T, Demir IE, Deneen B, Gutmann DH, Hervey-Jumper S, Kuner T,
Mabbott D, et al: Cancer neuroscience: State of the field, emerging
directions. Cell. 186:1689–1707. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tohme S, Simmons RL and Tsung A: Surgery
for cancer: A trigger for metastases. Cancer Res. 77:1548–1552.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Badwe RA, Parmar V, Nair N, Joshi S,
Hawaldar R, Pawar S, Kadayaprath G, Borthakur BB, Rao Thammineedi
S, Pandya S, et al: Effect of peritumoral infiltration of local
anesthetic before surgery on survival in early breast cancer. J
Clin Oncol. 41:3318–3328. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sessler DI, Pei L, Huang Y, Fleischmann E,
Marhofer P, Kurz A, Mayers DB, Meyer-Treschan TA, Grady M, Tan EY,
et al: Recurrence of breast cancer after regional or general
anaesthesia: A randomised controlled trial. Lancet. 394:1807–1815.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan
T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin MZ and Jin WL: The updated landscape
of tumor microenvironment and drug repurposing. Signal Transduct
Target Ther. 5:1662020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinha D, Sarkar N, Biswas J and Bishayee
A: Resveratrol for breast cancer prevention and therapy:
Preclinical evidence and molecular mechanisms. Semin Cancer Biol.
40–41. 209–232. 2016.
|
|
18
|
Gong F, Ma JC, Jia J, Li FZ, Wu JL, Wang
S, Teng X and Cui ZK: Synergistic effect of the anti-PD-1 antibody
with blood stable and reduction sensitive curcumin micelles on
colon cancer. Drug Deliv. 28:930–942. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu C, Iwasaki M, Liu Z, Wang B, Li X, Lin
H, Li J, Li JV, Lian Q and Ma D: Lung but not brain cancer cell
malignancy inhibited by commonly used anesthetic propofol during
surgery: Implication of reducing cancer recurrence risk. J Adv Res.
31:1–12. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su Z, Liu HL, Qi B and Liu Y: Effects of
propofol on proliferation and apoptosis of cardia cancer cells via
MAPK/ERK signaling pathway. Eur Rev Med Pharmacol Sci. 24:428–433.
2020.PubMed/NCBI
|
|
21
|
Peng Z and Zhang Y: Propofol inhibits
proliferation and accelerates apoptosis of human gastric cancer
cells by regulation of microRNA-451 and MMP-2 expression. Genet Mol
Res. 15:2016. View Article : Google Scholar
|
|
22
|
Du Q, Zhang X, Zhang X, Wei M, Xu H and
Wang S: Propofol inhibits proliferation and epithelial-mesenchymal
transition of MCF-7 cells by suppressing miR-21 expression. Artif
Cells Nanomed Biotechnol. 47:1265–1271. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Lu Y, Pang Y, Li M, Cheng X and Chen
J: Propofol enhances the cisplatin-induced apoptosis on cervical
cancer cells via EGFR/JAK2/STAT3 pathway. Biomed Pharmacother.
86:324–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang Y, Lei L and Liu Y: Propofol
improves sensitivity of lung cancer cells to cisplatin and its
mechanism. Med Sci Monit. 26:e9197862020.PubMed/NCBI
|
|
25
|
Gao Y, Zhou Y, Wang C, Sample KM, Yu X and
Ben-David Y: Propofol mediates pancreatic cancer cell activity
through the repression of ADAM8 via SP1. Oncol Rep. 46:2492021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fang P, Zhou J, Xia Z, Lu Y and Liu X:
Effects of propofol versus sevoflurane on postoperative breast
cancer prognosis: A narrative review. Front Oncol. 11:7930932021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Oh CS, Hong SW, Park S, Kwon Y and Kim SH:
Effect of equipotent doses of propofol and sevoflurane on
endoplasmic reticulum stress during breast cancer surgery. Korean J
Anesthesiol. 75:487–495. 2022.PubMed/NCBI
|
|
28
|
Li R, Liu H, Dilger JP and Lin J: Effect
of propofol on breast cancer cell, the immune system, and patient
outcome. BMC Anesthesiol. 18:772018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Liu M, Zeng B and Wang Z: Propofol
induces hepatocellular carcinoma cell apoptosis via regulating
miR-105/JAK2/STAT3 axis. Cytokine. 148:1556492021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Z, Liu H, Zhang Y and Tan H: The effect
of propofol on the proliferation and apoptosis of hepatocellular
carcinoma cells through TGF-Β1/Smad2 signaling pathway.
Bioengineered. 12:4581–4592. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Wang N, Zhou S, Ye W, Jing G and
Zhang M: Propofol induces proliferation and invasion of gallbladder
cancer cells through activation of Nrf2. J Exp Clin Cancer Res.
31:662012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Q, Sheng Z, Cheng C, Zheng H, Lanuti
M, Liu R, Wang P, Shen Y and Xie Z: Anesthetic propofol promotes
tumor metastasis in lungs via GABA(A) R-dependent TRIM21 modulation
of Src expression. Adv Sci (Weinh). 8:e21020792021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Monteran L, Ershaid N, Doron H, Zait Y,
Scharff Y, Ben-Yosef S, Avivi C, Barshack I, Sonnenblick A and Erez
N: Chemotherapy-induced complement signaling modulates
immunosuppression and metastatic relapse in breast cancer. Nat
Commun. 13:57972022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dong J, Zhu C, Zhang F, Zhou Z and Sun M:
‘Attractive/adhesion force’ dual-regulatory nanogels capable of
CXCR4 antagonism and autophagy inhibition for the treatment of
metastatic breast cancer. J Control Release. 341:892–903. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang J, Dong Z, Ren A, Fu G, Zhang K, Li
C, Wang X and Cui H: Antibiotic tigecycline inhibits cell
proliferation, migration and invasion via down-regulating CCNE2 in
pancreatic ductal adenocarcinoma. J Cell Mol Med. 24:4245–4260.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Speck C, Chen Z, Li H and Stillman B:
ATPase-dependent cooperative binding of ORC and Cdc6 to origin DNA.
Nat Struct Mol Biol. 12:965–971. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lim N and Townsend PA: Cdc6 as a novel
target in cancer: Oncogenic potential, senescence and subcellular
localisation. Int J Cancer. 147:1528–1534. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu KC, Liao KS, Yeh LR and Wang YK: Drug
repurposing: The mechanisms and signaling pathways of anti-cancer
effects of anesthetics. Biomedicines. 10:15892022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Skues MA and Prys-Roberts C: The
pharmacology of propofol. J Clin Anesth. 1:387–400. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Walsh CT: Propofol: Milk of Amnesia. Cell.
175:10–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shashni B, Nishikawa Y and Nagasaki Y:
Management of tumor growth and angiogenesis in triple-negative
breast cancer by using redox nanoparticles. Biomaterials.
269:1206452021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang Q, Chen Z, Qiu Y, Huang W, Wang T,
Song L, Sun X, Li C, Xu X and Kang L: Theranostic role of (89)Zr-
and (177)Lu-labeled aflibercept in breast cancer. Eur J Nucl Med
Mol Imaging. 51:1246–1260. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Alboabdullah AKA, Goodarzi MT and
Homayouni Tabrizi M: The Lawson-loaded β-cyclodextrin nanocarriers
(LB-NCs) a novel targeted cancer cell in stomach and breast cancer
as a drug delivery system. Naunyn Schmiedebergs Arch Pharmacol. Mar
14–2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mailand N and Diffley JFX: CDKs promote
DNA replication origin licensing in human cells by protecting Cdc6
from APC/C-dependent proteolysis. Cell. 122:915–926. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sieuwerts AM, Look MP, Meijer-van Gelder
ME, Timmermans M, Trapman AMAC, Garcia RR, Arnold M, Goedheer AJW,
de Weerd V, Portengen H, et al: Which cyclin E prevails as
prognostic marker for breast cancer? Results from a retrospective
study involving 635 lymph node-negative breast cancer patients.
Clin Cancer Res. 12:3319–3328. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bömer M, Pérez-Salamó I, Florance HV,
Salmon D, Dudenhoffer JH, Finch P, Cinar A, Smirnoff N, Harvey A
and Devoto A: Jasmonates induce Arabidopsis bioactivities
selectively inhibiting the growth of breast cancer cells through
CDC6 and mTOR. New Phytol. 229:2120–2134. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Feng C, Qian D and Chen C: A meta-analysis
and systematic review of propofol on liver ischemia-reperfusion
injury protection during hepatocellular carcinoma anesthesia
surgery. Ann Palliat Med. 10:6726–6735. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sen Y, Xiyang H and Yu H: Effect of
thoracic paraspinal block-propofol intravenous general anesthesia
on VEGF and TGF-β in patients receiving radical resection of lung
cancer. Medicine (Baltimore). 98:e180882019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jaura AI, Flood G, Gallagher HC and Buggy
DJ: Differential effects of serum from patients administered
distinct anaesthetic techniques on apoptosis in breast cancer cells
in vitro: A pilot study. Br J Anaesth. 113 (Suppl 1):i63–i67. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim R: Anesthetic technique and cancer
recurrence in oncologic surgery: Unraveling the puzzle. Cancer
Metastasis Rev. 36:159–177. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Greenfeld K, Avraham R, Benish M, Goldfarb
Y, Rosenne E, Shapira Y, Rudich T and Ben-Eliyahu S: Immune
suppression while awaiting surgery and following it: Dissociations
between plasma cytokine levels, their induced production, and NK
cell cytotoxicity. Brain Behav Immun. 21:503–513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kushida A, Inada T and Shingu K:
Enhancement of antitumor immunity after propofol treatment in mice.
Immunopharmacol Immunotoxicol. 29:477–486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Inada T, Yamanouchi Y, Jomura S, Sakamoto
S, Takahashi M, Kambara T and Shingu K: Effect of propofol and
isoflurane anaesthesia on the immune response to surgery.
Anaesthesia. 59:954–959. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yap A, Lopez-Olivo MA, Dubowitz J, Hiller
J and Riedel B; Global Onco-Anesthesia Research Collaboration
Group, : Anesthetic technique and cancer outcomes: A meta-analysis
of total intravenous versus volatile anesthesia. Can J Anaesth.
66:546–561. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kim R: Effects of surgery and anesthetic
choice on immunosuppression and cancer recurrence. J Transl Med.
16:82018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Korn EL, Moscow JA and Freidlin B: Dose
optimization during drug development: Whether and when to optimize.
J Natl Cancer Inst. 115:492–497. 2023. View Article : Google Scholar : PubMed/NCBI
|
